Aminopyrazole-phenylalanine based GPR142 agonists: Discovery of tool compound and in vivo efficacy studies

ACS Medicinal Chemistry Letters

Volumn 4, Issue 9, 2013, Pages 829-834

  Yu, Ming ^a   Lizarzaburu, Mike ^a   Motani, Alykhan ^a   Fu, Zice ^a   Du, Xiaohui ^a   Liu, Jiwen ^a   Jiao, Xianyun ^a   Lai, Sujen ^a   Fan, Peter ^a   Fu, Angela ^a   Liu, Qingxiang ^a   Murakoshi, Michiko ^b   Nara, Futoshi ^b   Oda, Kozo ^b   Okuyama, Ryo ^b   Reagan, Jeff D ^a   Watanabe, Nobuaki ^b   Yamazaki, Mami ^b   Xiong, Yumei ^a   Zhang, Ying ^a   Zhuang, Run ^a   Lin, Daniel C H ^a   Houze, Jonathan B ^a   Medina, Julio C ^a   Li, Leping ^a,c   more..

^a AMGEN INC   (United States)

^b DAIICHI SANKYO CO   (Japan)

^c Presidio Pharmaceuticals Inc   (United States)

Author keywords

aminopyrazole phenylalanine; GPR142 agonist; human islet transplant; insulin secretagogue; oral glucose tolerance test; prodrug; type 2 diabetes

Indexed keywords

AMRINONE; CARBOXYLIC ACID; CYTOCHROME P450; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 142; PHENYLALANINE DERIVATIVE; PYRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; AMINATION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; IN VIVO STUDY; INSULIN RELEASE; LIVER MICROSOME; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION;

EID: 84884231012     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml4000854     Document Type: Article

References (6)

1. Fredriksson, R.; Hoglund, P. J.; Gloriam, D. I.; Lagerstrom, M. C.; Schioth, H. B. Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives FEBS Lett. 2003, 554, 381-388
2. Suesens, U.; Hermans-Borgmeyer, I.; Urny, J.; Schaller, H. C. Characterisation and differential expression of two very closely related G-protein-coupled receptors, GPR139 and GPR142, in mouse tissue and during mouse development Neuropharmacology 2006, 50, 512-520
3. Xiong, Y.; Motani, A.; Reagan, J.; Gao, X.; Yang, H.; Ma, J.; Schwandner, R.; Zhang, Y.; Liu, Q.; Miao, L.; Luo, J.; Tian, H.; Chen, J.-L.; Murakoshi, M.; Nara, F.; Yeh, W.-C.; Cao, Z. Submitted for publication.
4. Lizarzaburu, M.; Turcotte, S.; Du, X.; Duqutte, J.; Fu, A.; Houze, J.; Li, L.; Liu, J.; Oda, K.; Okuyama, R.; Reagan, J. D.; Yu, M.; Medina, J. C. Discovery and optimization of a novel series of GPR142 agonists for the treatment of type 2 diabetes mellitus Bioorg. Med. Chem. Lett. 2012, 22, 5942-5947
5. Du, X.; Kim, Y.-J.; Lai, S.; Chen, X.; Lizarzaburu, M.; Turcotte, S.; Oda, K.; Okuyama, R.; Nara, F.; Murakoshi, M.; Fu, A.; Reagan, J.; Liu, Q.; Zhang, Y.; Motani, A.; Fan, P.; Xiong, Y.; Shen, W.; Li, L.; Houze, J.; Medina, J. C. Phenylalanine derivatives as GPR142 agonists for the treatment of Type II diabetes Bioorg. Med. Chem. Lett. 2012, 22, 6218-6223
6. Jansson, J.; Eizirik, D. L.; Pipeleers, D. G.; Hakan Borg, L. A.; Hellerstrom, C.; Andersson, A. Impairment of glucose-induced insulin secretion in human pancreatic islets transplanted to diabetic nude mice J. Clin. Invest. 1996, 96, 721-726